drug
latanoprostene bunod
Marketedupdated 3mo agoby $BLCO Bausch & Lomb Corp
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying latanoprostene bunod
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 21, 2029
~2.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Feb 21, 2029compositionUS 80584672.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 13m ago
Found something off?
comments(0)
5-min edit window · permanent after that